Are we Choosing Wisely in lymphoma? Excessive use of surveillance CT imaging in patients with diffuse large B-cell lymphoma (DLBCL) in long-term remission

The use of surveillance computed tomography (CT) imaging in patients with diffuse large B-cell lymphoma (DLBCL) in remission is neither effective nor cost-effective. The American Society of Hematology (ASH) Choosing Wisely (CW) campaign, in particular, emphasizes the lack of benefit beyond 2-years of completion of therapy. We sought to describe the real-world practice of surveillance imaging.
Source: Clinical Lymphoma, Myeloma and Leukemia - Category: Hematology Authors: Tags: Original Study Source Type: research

Related Links:

ConclusionOur study has shown that 90% of PTCL cases will be FDG avid. However, PET/CT was not predictive for PFS or OS at any point. The only predictive factor was the presence of lymphopenia.
Source: Clinical Lymphoma Myeloma and Leukemia - Category: Cancer & Oncology Source Type: research
ConclusionAlthough patients with MYC-R lymphoma are reported to be at high risk for primary treatment failure, this is not predicted by iPET +, and it is not recommended that the result of iPET be used to guide changes in management of front-line or consolidative therapy for these patients.
Source: Clinical Lymphoma Myeloma and Leukemia - Category: Cancer & Oncology Source Type: research
Conclusion18F-FDG PET/CT showed high diagnostic performance in the evaluation of BMI in pediatric HL. Thus, BMB should be ideally reserved for patients presenting with doubtful 18F-FDG PET/CT findings for BMI.
Source: Clinical Lymphoma Myeloma and Leukemia - Category: Cancer & Oncology Source Type: research
ConclusionAlthough patients with MYC-R lymphoma are reported to be at high risk for primary treatment failure, this is not predicted by iPET +, and it is not recommended that the result of iPET be used to guide changes in management of front-line or consolidative therapy for these patients.
Source: Clinical Lymphoma Myeloma and Leukemia - Category: Cancer & Oncology Source Type: research
Conclusion18F-FDG PET/CT showed high diagnostic performance in the evaluation of BMI in pediatric HL. Thus, BMB should be ideally reserved for patients presenting with doubtful 18F-FDG PET/CT findings for BMI.
Source: Clinical Lymphoma Myeloma and Leukemia - Category: Cancer & Oncology Source Type: research
We examined the role of positron emission tomography/computed tomography (PET/CT) in a retrospective study of 40 patients. Of the 40 patients, 90% had fluorine-18 fluorodeoxyglucose-avid findings on PET/CT at diagnosis. The interim PET/CT and end of treatment PET/CT results were not prognostic for progression-free survival (PFS) or overall survival (OS). On multivariate analysis, only lymphopenia remained prognostic for PFS and OS.
Source: Clinical Lymphoma, Myeloma and Leukemia - Category: Hematology Authors: Tags: Original Study Source Type: research
Non –Burkitt B-cell lymphoma with a rearrangement of MYC is an aggressive lymphoma that can fail initial treatment. We reviewed the data from 28 patients and investigated whether the mid-treatment positron emission tomography/computed tomography (PET/CT) scan could predict treatment failure. The results of that PET/CT scan did not predict in which patients the initial treatment would fail. Therefore, it should not be used to guide treatment decisions in this population.
Source: Clinical Lymphoma, Myeloma and Leukemia - Category: Hematology Authors: Tags: Original Study Source Type: research
Patients diagnosed with MYC-rearranged non-Burkitt aggressive B cell lymphoma (MYC-R), including those with double hit lymphoma, are at high risk for developing relapsed/refractory disease, even if treated with intensive front-line immunochemotherapy. It is common in clinical practice as well as clinical trials to perform an interim PET-CT scan (iPET) during front-line therapy for diffuse large B cell lymphoma, however the utility of iPET result in MYC-R patients with regards to predicting outcomes is unclear.
Source: Clinical Lymphoma, Myeloma and Leukemia - Category: Hematology Authors: Tags: Original Study Source Type: research
Conclusions:Whole body PET/CT is useful for the detection of subcutaneous ENMZL, which have a unique lentiform shape and low FDG avidity, with a typical distribution. Detection of subcutaneous lesions may affect disease staging, and decisions regarding follow up and treatment.
Source: Journal of Nuclear Medicine - Category: Nuclear Medicine Authors: Tags: Leukemia/Lymphoma/Myeloma Poster Session Source Type: research
1417Objectives: To analyze the relationship between the SUVmax decrease proportion(SUVmax% )and MYC gene in diffuse large B-cell lymphoma (DLBCL), and evaluate the prognostic value on 18F-FDG PET/CT imaging and MYC gene in DLBCL. To study the SUVmax% and Deauville 5-point scale in the different phase of chemotherapy and reserch the optimal time point . Methods 171 patients (87 males, 84 females, average age 50.66±2.56 (12-81) years) with pathologically confirmed DLBCL were analyzed. 18F-FDG PET/CT were performed before and after different courses of chemotherapy (60 patients in early phase, 55 patients in medium pha...
Source: Journal of Nuclear Medicine - Category: Nuclear Medicine Authors: Tags: Leukemia/Lymphoma/Myeloma Poster Session Source Type: research
More News: CT Scan | Hematology | Leukemia | Lymphoma | Myeloma | Study